Phio PharmaceuticalsPHIO -0.97%28 Pretax Margin % is % as of Mar. 2026. GuruFocus rates PHIO with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 939 Biotechnology companies, Phio Pharmaceuticals ranks worse than 106496.17% on this metric.
The historical rank and industry rank for Phio Pharmaceuticals's Pretax Margin % or its related term are showing as below:
PHIO's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.42 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Phio Pharmaceuticals Pretax Margin % Related Terms
Phio Pharmaceuticals Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Phio Pharmaceuticals's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHIO vs PBM, KPRX, OSRH: Pretax Margin % Comparison
For the Biotechnology subindustry, Phio Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phio Pharmaceuticals Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Phio Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phio Pharmaceuticals (PHIO) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Phio Pharmaceuticals and its competitors. According to the industry distribution chart, Phio Pharmaceuticals ranks #999999 out of 939 companies in the Biotechnology industry.
Is Phio Pharmaceuticals' Pretax Margin % too high?
Phio Pharmaceuticals' current Pretax Margin % is %. Based on the distribution chart, Phio Pharmaceuticals ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Phio Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Phio Pharmaceuticals' Pretax Margin % compare to PBM and KPRX?
According to the Biotechnology industry distribution chart, Phio Pharmaceuticals ranks #999999 out of 939 companies for Pretax Margin %. This places Phio Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Phio Pharmaceuticals and its competitors. Phio Pharmaceuticals's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phio Pharmaceuticals stock overvalued right now?
Phio Pharmaceuticals (PHIO) has a current Pretax Margin % of %. The current Pretax Margin % is %. Phio Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Phio Pharmaceuticals (PHIO), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
28GF Score
Get the complete analysis for PHIO
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHIO has been successfully added to your 
